Fact-checked by Grok 2 weeks ago

Chancroid

Chancroid is a sexually transmitted bacterial infection caused by the gram-negative bacterium Haemophilus ducreyi, primarily characterized by the development of painful, soft genital ulcers and, in approximately half of cases, tender inguinal lymphadenopathy that may progress to suppurative buboes. The infection typically manifests 3 to 10 days after exposure, beginning as a tender papule that erodes into a ragged, purulent ulcer with undermined edges, often accompanied by regional lymph node inflammation due to bacterial invasion and toxin-mediated tissue necrosis. Transmission occurs almost exclusively through direct sexual contact with an infected individual, though rare non-sexual transmission can occur, particularly among children in endemic areas through direct contact with open sores or exudate; it disproportionately affects uncircumcised men and is a known cofactor in facilitating HIV acquisition by disrupting mucosal barriers. Globally, chancroid remains more prevalent in resource-limited regions of , , and parts of the , where it contributes to genital ulcer disease syndromes, but it has significantly declined in industrialized countries, including fewer than 10 reported cases annually in the United States since the due to improved control measures. The disease is underdiagnosed worldwide owing to its similarity to other ulcerative STIs like and , compounded by the limited availability of specialized diagnostic tests such as culture media for H. ducreyi, which have a of less than 80%, or emerging assays not yet widely approved. Without treatment, ulcers may heal spontaneously over weeks to months but carry risks of secondary bacterial , scarring, or chronic complications like fistulas; however, prompt therapy—such as a single dose of or —effectively cures the infection, resolves symptoms, and prevents further transmission, with follow-up essential to monitor healing and exclude coinfections.

Clinical Presentation

Signs and Symptoms

Chancroid typically has an of 3 to 10 days following exposure. The infection begins with the appearance of a small, tender or pustule at the site of , which rapidly evolves into a painful within a few days. The characteristic , often termed a "soft ," is painful and features ragged, undermined edges with a purulent, friable base covered by yellow-gray ; it typically measures 1 to 2 cm in diameter, though lesions may coalesce or vary in size. This pain distinguishes chancroid ulcers from the painless lesions seen in conditions like primary . In 25% to 50% of cases, tender inguinal develops, forming fluctuant buboes that are often unilateral and may suppurate, rupture, or form abscesses requiring drainage. Systemic symptoms such as fever and are uncommon but may occur in severe cases involving multiple lesions or extensive . Co-infection with can worsen the presentation, leading to more extensive ulcers and delayed healing.

Sites of Lesions

In males, chancroid lesions most commonly develop on the penile shaft, , coronal sulcus, or , reflecting sites of direct contact during sexual . These locations are favored due to the anatomy of the , where microtrauma facilitates bacterial entry. Less frequently, lesions appear on the or perianal area, particularly in cases involving anal intercourse. In females, the lesions frequently occur on the , , or , areas prone to and exposure during heterosexual or same-sex contact. In some instances, involvement extends to the or vaginal walls, often going unnoticed without internal . These sites contribute to the higher likelihood of multiple or internal lesions in women compared to men. Extragenital lesions are uncommon but can arise from oral or anal sexual , manifesting on the inner thighs, , or other nearby surfaces through direct transfer. Multiple lesions are observed in 30-70% of untreated cases, typically resulting from autoinoculation where spread from the initial site via self-contact or apposition of surfaces, such as "kissing ulcers" between opposing areas. This progression underscores the importance of early to limit dissemination.

Complications

Untreated chancroid often progresses from initial genital ulceration to regional , which serves as a precursor to more severe complications. In approximately 25% to 50% of cases, this becomes suppurative, forming painful inguinal buboes that may rupture spontaneously, leading to chronic drainage or formation in advanced stages. These , resulting from deep tissue destruction and secondary bacterial , can create persistent urogenital or rectal tracts, contributing to ongoing morbidity even after resolution of the primary infection. Genital scarring is a common of unresolved ulcers and rupture, particularly affecting the penile in males and causing or urethral strictures that may lead to urinary obstruction. In females, scarring can involve vulvar tissues, potentially resulting in adhesions or fistulas that complicate or . These structural changes arise from the necrotizing effects of and associated anaerobic superinfections, such as those involving or species. The ulcerative lesions of chancroid significantly elevate the risk of HIV transmission and acquisition, with estimates indicating up to a 10- to 100-fold increase per sexual act due to disruption of the genital mucosa and recruitment of HIV-susceptible immune cells. This facilitation occurs through enhanced viral entry via upregulated co-receptors like and on local macrophages and + T cells. Chancroid frequently co-occurs with other sexually transmitted infections, such as and , owing to overlapping high-risk sexual behaviors in affected populations. In regions with high prevalence, co-infection rates with or can reach 15% to 37% among those presenting with genital ulcers.

Etiology and Pathogenesis

Causative Agent

Chancroid is caused by , a fastidious, Gram-negative that is facultatively . This bacterium requires (X factor) for growth but does not need (V factor), distinguishing it from other Haemophilus species like H. influenzae. It is non-motile and grows optimally on enriched media, such as , under conditions of high humidity and 5–10% CO₂ at 33–35°C. On Gram staining, H. ducreyi appears as short, parallel chains of organisms, often described as a "school of fish" or "railroad track" pattern due to its staining and arrangement. Biochemically, it is typically oxidase-positive and catalase-negative, with limited fermentative activity and no production. The species comprises two distinct genetic classes: Class I, which is the most prevalent worldwide and associated with both genital ulcers and cutaneous infections, and Class II, which has been primarily reported from regions such as and parts of the South Pacific. Transmission of H. ducreyi occurs exclusively through direct skin-to-skin contact, primarily during sexual activity, as the bacterium survives poorly outside the human host—typically no more than 2–4 hours on surfaces like swabs. It is an obligate human pathogen with no known zoonotic . human carriage on intact skin has been documented, and recent evidence indicates potential environmental contamination via fomites and insects (e.g., flies) may facilitate transmission in endemic areas.

Pathogenesis

Haemophilus ducreyi, the causative agent of chancroid, initiates infection by attaching to host epithelial cells, primarily , through specialized surface structures. The bacterium employs pili and outer membrane proteins, notably the trimeric autotransporter adhesin DsrA, which is necessary and sufficient for binding to keratinocyte cell lines such as HaCaT cells, facilitating adherence without invasion. This attachment allows H. ducreyi to colonize the mucosal surface and evade initial by host immune cells; large surface-associated proteins like LspA1 and LspA2 bind host factors such as and , inhibiting opsonization and engulfment by macrophages and neutrophils. in experimental human models confirms that bacteria colocalize with at lesion sites but remain extracellular, underscoring this extracellular lifestyle as a key survival strategy. Following attachment, H. ducreyi contributes to tissue damage through the production of factors, including the cytolethal distending toxin (HdCDT), a tripartite that induces DNA damage and G2/M arrest in host cells. HdCDT, comprising CdtA, CdtB (the active DNase subunit), and CdtC, leads to cellular distension, , and in epithelial cells, promoting the breakdown of the mucosal barrier and development. Although HdCDT mutants can still form initial pustules in human challenge models, the exacerbates lesion severity and formation in animal models, highlighting its role in amplifying tissue destruction. To persist within the host, H. ducreyi employs mechanisms of immune evasion, including the formation of biofilm-like microcolonies on surfaces that shield bacteria from and phagocytic killing. These structured communities, observed in experimental infections, inhibit function by resisting engulfment and promoting a suppurative environment rich in polymorphonuclear leukocytes that fail to clear the . Additionally, the bacterium suppresses activation through secreted factors and surface proteins, further dampening innate immune responses. Recent studies using experimental human models and have elucidated responses, including recruitment of plasmacytoid dendritic cells and M1-like macrophages, and tryptophan catabolism via () at sites. genetic factors, such as polymorphisms in TLR9 and IL-10, contribute to . Both I and II strains exhibit similar biological potential in causing genital and cutaneous infections. The spreads locally via lymphatic channels, disseminating to regional nodes and inducing formation through the release of pro-inflammatory cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α) from infected and recruited immune cells. This cytokine-mediated drives lymphadenitis and development. Chancroid also enhances susceptibility by breaching the epithelial barrier, creating portals for viral entry, and recruiting activated + T cells expressing co-receptors and to sites, thereby increasing local and risk.

Diagnosis

Clinical Evaluation

The clinical evaluation of chancroid begins with a detailed patient history to identify risk factors and contextualize symptoms. Clinicians should inquire about recent sexual exposure, particularly unprotected intercourse with multiple partners, as chancroid is primarily transmitted through sexual contact. A history of travel to endemic areas, such as parts of , , or the , is particularly relevant, given the disease's rarity in non-endemic regions like the and . The typically ranges from 3 to 10 days following exposure, and patients often report the onset of painful genital lesions, which helps distinguish chancroid from painless ulcers seen in primary . Additionally, history should explore potential non-infectious causes, such as , to exclude mimics through absence of sexual risk factors or presence of alternative explanations like . Physical examination focuses on genital and inguinal regions to assess characteristics and . Chancroid typically presents with one or more tender, superficial ulcers measuring 1-2 cm, featuring ragged or undermined edges, a friable base with yellow-gray , and no significant induration, contrasting with the hard, clean-based of . Inguinal occurs in approximately 50% of cases, often unilateral and tender, potentially progressing to fluctuant buboes in 25% of patients within 1-2 weeks. The ulcers are most common on the coronal sulcus, , or in men and the , , or perianal area in women, with easy bleeding upon palpation. In resource-limited settings, the recommends a syndromic approach for presumptive and of painful genital ulcers without vesicles or induration, treating them as chancroid-like to ensure rapid intervention where laboratory facilities are unavailable. Evaluation should also consider co-infections, as chancroid frequently co-occurs with other sexually transmitted infections; thus, testing is advised at presentation due to the disease's role as a cofactor in HIV transmission and altered clinical course in immunocompromised individuals. Screening for and is essential to guide differential considerations, though definitive exclusion relies on clinical judgment during initial assessment.

Laboratory Confirmation

Laboratory confirmation of chancroid involves several diagnostic tests aimed at detecting , the causative bacterium, though challenges in and availability limit their routine use. of can reveal characteristic "school of fish" or chain-like arrangements of gram-negative rods, but this method has low (30-80%) and poor specificity due to the presence of other genital flora. Culture remains the traditional gold standard for definitive diagnosis, requiring inoculation of specimens from the ulcer base onto selective media such as chocolate agar supplemented with vancomycin (3 μg/mL) to inhibit overgrowth by other bacteria. However, H. ducreyi is fastidious and requires immediate plating or transport under specific conditions, resulting in sensitivities of 50-80%, which are even lower in women and when commercial media are unavailable. Polymerase chain reaction (PCR) assays targeting genes such as hhdA (encoding ) or groEL () offer the highest sensitivity (90-100%) and specificity (97-98%), making them increasingly preferred where available, though no FDA-cleared tests exist and results may be delayed. Some multiplex amplification tests (NAATs) for sexually transmitted infections now include H. ducreyi detection in specialized laboratories. Serological tests are generally not useful for diagnosis due to cross-reactivity with other Haemophilus species and slow antibody development, limiting their reliability in acute settings. Key challenges in laboratory confirmation include overgrowth of commensal flora in non-selective cultures, the need for prompt specimen processing to maintain viability, and limited access to specialized media or molecular testing in resource-poor areas where chancroid is prevalent.

Differential Diagnosis

Chancroid must be differentiated from other causes of genital ulceration, particularly other sexually transmitted infections that present with similar lesions. The is suggested by the presence of one or more painful, deep, ragged-edged ulcers with undermined borders and purulent base, often accompanied by tender suppurative inguinal adenopathy, in the absence of evidence for alternative etiologies. Syphilis, caused by , typically presents with a single, painless characterized by indurated edges and a clean base, which appears 10–90 days after exposure and heals spontaneously within 3–6 weeks. In contrast, chancroid ulcers are painful and lack induration. Serologic testing, including nontreponemal tests like (RPR) and treponemal tests like fluorescent treponemal antibody absorption (FTA-ABS), is positive in syphilis, helping to rule it out in suspected chancroid cases. Genital herpes, due to herpes simplex virus types 1 or 2 (-1 or -2), begins with clusters of vesicles that rupture to form multiple shallow, painful ulcers, often accompanied by systemic symptoms such as fever, , and inguinal during the initial outbreak. Chancroid lesions are typically deeper, solitary or few, and lack the vesicular , though both are painful. Nucleic acid amplification testing (NAAT) or (PCR) on ulcer exudate confirms and excludes it from the differential. Lymphogranuloma venereum (LGV), caused by serovars L1, L2, or L3, features a transient, often unnoticed primary or that resolves quickly, followed by prominent, tender inguinal buboes that may suppurate and form tracts. Unlike chancroid, where ulcers persist and adenopathy develops concurrently, LGV emphasizes over persistent ulceration. Diagnosis relies on or NAAT for C. trachomatis, with serovar typing if available. Granuloma inguinale (donovanosis), caused by granulomatis (formerly Calymmatobacterium granulomatis), manifests as chronic, painless, beefy-red ulcerative lesions with exuberant and little , progressing slowly without significant adenopathy. Chancroid ulcers, by comparison, are acute, painful, and purulent. Visualization of intracellular Donovan bodies on tissue crush preparation or confirms the . Non-infectious causes, such as trauma from sexual injury or Behçet's disease—a systemic vasculitis featuring recurrent oral and genital ulcers along with uveitis or skin lesions—should be considered when infectious etiologies are excluded. Traumatic ulcers are irregular and history-dependent, while Behçet's ulcers may be painful but occur in the context of multisystem involvement. Biopsy may be necessary for atypical or persistent lesions to identify non-infectious pathology. A key differentiator for chancroid is the combination of painful ulceration without systemic rash or vesicular elements, though laboratory confirmation via culture or NAAT for Haemophilus ducreyi is ideal when available.

Prevention and Control

Preventive Strategies

Preventive strategies for chancroid focus on reducing sexual transmission through behavioral modifications and interventions, as the infection is primarily spread via direct contact with open sores during sexual activity. Consistent and correct use of latex condoms has been shown to reduce the risk of chancroid transmission, particularly during vaginal and , by providing a barrier that limits skin-to-skin contact with genital ulcers. Individuals in endemic areas are advised to avoid high-risk behaviors, such as engaging in sex work or unprotected sex with multiple partners, to minimize exposure in regions where prevalence remains elevated. Partner notification and contact tracing are essential components of chancroid control, following established guidelines from the Centers for Disease Control and Prevention (CDC) and (WHO). These processes involve identifying and promptly examining sexual partners who had contact with an infected individual within 10 days prior to symptom onset, regardless of whether symptoms are present, to enable early and interrupt chains. In outbreak settings, syndromic management—treating patients based on clinical presentation of genital ulcers without waiting for laboratory confirmation—facilitates rapid response, while routine screening and of high-risk groups, such as sex workers, have proven effective in curbing spread through targeted interventions. Public education plays a critical role in prevention by promoting recognition of early symptoms, such as painful genital ulcers with ragged edges and suppurative bases, and encouraging individuals to seek medical care promptly to avoid complications and further transmission. These efforts are most impactful when integrated into broader (STI) prevention programs, which combine counseling, testing, and referral services to address multiple STIs simultaneously and enhance overall outcomes.

Vaccine Development

There is currently no licensed vaccine available for chancroid, caused by , though research has centered on outer membrane proteins such as the trimeric autotransporter adhesin DsrA as promising candidates. DsrA facilitates bacterial adherence to host cells and confers resistance to serum killing, making it a key targeted for strategies. Preclinical studies have demonstrated the and protective potential of recombinant DsrA (rDsrA). In models, with the N-terminal domain of DsrA (rNT-DsrA) combined with adjuvants like , CpG, or elicited high-titer, persistent humoral responses that recognized the bacterial surface, with antibody titers maintained for over 200 days post-. In the model of chancroid, which closely mimics human genital ulceration, vaccination with rNT-DsrA protected against experimental challenge with homologous H. ducreyi strains, significantly reducing formation and bacterial compared to controls. These findings highlight DsrA's role in generating protective antibodies, though was limited against strains. As of 2025, vaccine development remains in the preclinical stage, with no clinical trials reported. A chancroid could indirectly aid prevention, as genital ulcers from H. ducreyi are estimated to increase per-act transmission risk by 10- to 100-fold through disruption of mucosal barriers and recruitment of HIV-susceptible immune cells. Key challenges include antigenic variability in DsrA's N-terminal region between class I and class II H. ducreyi biotypes, which reduces cross-protection, and the need to induce robust mucosal immunity at genital sites for effective prevention of sexual transmission. Additionally, H. ducreyi's fastidious growth requirements have historically hampered large-scale production and study.

Treatment and Management

Antibiotic Regimens

The recommended first-line antibiotic regimens for chancroid, according to the Centers for Disease Control and Prevention (CDC), include a single oral dose of 1 g or a single intramuscular dose of ceftriaxone 250 mg; these single-dose options facilitate adherence and observed compliance. Alternative regimens encompass ciprofloxacin 500 mg orally twice daily for 3 days or erythromycin base 500 mg orally three times daily for 7 days, which may be considered based on local availability and patient factors. The (WHO) endorses syndromic management for genital ulcers that aligns with these antimicrobial choices, emphasizing effective coverage against . In patients co-infected with , single-dose regimens like or show limited efficacy and higher failure rates; extended with erythromycin 500 mg orally four times daily for 7 days is preferred to address potential slower response and persistent infection. Antimicrobial resistance patterns for H. ducreyi include intermediate resistance to quinolones such as , with reports of increasing prevalence in endemic areas of and ; monitoring through culture and susceptibility testing is essential, particularly in regions with limited data. Sexual partners who had contact with the within 10 days of symptom onset should receive presumptive , irrespective of symptoms, to prevent reinfection and further . Successful typically results in ulcer healing within 7-14 days, with symptoms improving subjectively in 3 days and objectively in 7 days; fluctuant buboes often require needle to promote resolution and avoid complications like rupture. For pregnant individuals, quinolones like are contraindicated due to risks of in the ; erythromycin is the preferred alternative, with as an option if tolerated. A brief clinical follow-up at 3-7 days post-treatment is recommended to confirm response and evaluate for cure.

Follow-up and Monitoring

Patients should be re-examined 3–7 days after initiating antibiotic therapy to assess clinical improvement in ulcers and lymphadenopathy. Symptomatically, ulcers typically improve within 3 days, with objective healing evident by 7 days, though complete resolution of large ulcers may require more than 2 weeks, particularly in uncircumcised men or those with HIV co-infection. If no improvement occurs, clinicians should evaluate for treatment failure, misdiagnosis, nonadherence, antimicrobial resistance, or coexisting conditions such as HIV. A routine test-of-cure is not recommended if symptoms resolve, but for persistent ulcers or buboes at 1 week, repeat or testing may be performed to confirm eradication of . Fluctuant buboes that do not resolve require management through needle aspiration or under to prevent complications like formation; incision is preferred to minimize repeat procedures. Counseling is essential post-treatment, advising from sexual activity or use until lesions heal completely and all partners are treated to prevent reinfection and transmission. partners with contact within 10 days before symptom onset should receive presumptive regardless of symptoms, along with STI screening. Patients should undergo rescreening for and other STIs, such as , at 3 months post-diagnosis, especially if initial tests were negative. In outbreak settings, chancroid cases are reportable to authorities, necessitating , partner notification, and enhanced surveillance to control spread.

Prognosis and Outcomes

Short-term Prognosis

With appropriate regimens, such as a single 1 g dose of or 250 mg intramuscular , chancroid achieves high cure rates in uncomplicated cases, leading to rapid symptomatic relief and prevention of transmission. Ulcers generally improve symptomatically within 3 days and show objective resolution within 7 days, with full healing occurring in 1-2 weeks for most patients. Inguinal buboes, when present, heal more slowly, typically requiring 2-4 weeks for resolution, and fluctuant may necessitate needle or to prevent complications. Treatment failure occurs in about 5-10% of cases, primarily due to , poor adherence, or incorrect initial . HIV-positive individuals experience lower treatment response rates and prolonged healing times, underscoring the importance of early and potentially extended courses. Recurrence is rare following successful if sexual partners are evaluated and treated, though reinfection risk remains linked to ongoing high-risk sexual behaviors. Follow-up protocols, including clinical reassessment within 3-7 days, help confirm resolution and detect any early failures. As of 2025, these outcomes align with the 2021 CDC and WHO guidelines, with no major updates reported.

Long-term Considerations

Untreated chancroid can lead to permanent genital scarring, particularly in advanced cases, which may result in or urethral obstruction in affected individuals. This scarring arises from the healing of persistent ulcers and is more common when the infection is not addressed promptly, potentially causing long-term discomfort during sexual activity or urination. If inguinal buboes suppurate without , they can progress to or the formation of fistulas, leading to ongoing tissue damage and recurrent infections in the genital or rectal areas. Such complications may require surgical intervention and can impair lymphatic drainage, contributing to persistent swelling and pain over extended periods. Chancroid facilitates persistence in co-infected individuals by increasing from genital ulcers, thereby enhancing transmission risk by 10- to 100-fold per sexual act. This synergy occurs through mechanisms such as providing an entry portal for and recruiting inflammatory cells that express HIV co-receptors, promoting and infectivity in endemic regions. Unlike some other STIs such as or , there is no established evidence linking chancroid to , with research emphasizing its role primarily in co-infection dynamics instead.

Epidemiology

Global Distribution

Chancroid remains exceedingly rare in developed countries, including the , where it is a nationally notifiable sexually transmitted infection with fewer than 100 cases reported annually on average. In 2025, 10 cases were reported year-to-date as of September 6 to the Centers for Disease Control and Prevention (CDC). This low incidence reflects effective surveillance and control measures in high-resource settings, though sporadic outbreaks can still occur in areas associated with sex networks. In contrast, chancroid is endemic in low- and middle-income regions, particularly , parts of , and , where it continues to contribute significantly to disease. These areas report higher prevalence among high-risk populations, such as female sex workers, with historical incidence rates among this group ranging from 1% to 10% of genital ulcers in affected communities. The disease is often linked to socioeconomic challenges, including , which facilitates transmission in overcrowded urban environments. Globally, the incidence of chancroid has declined substantially since the 1990s, largely attributable to the widespread adoption of syndromic management protocols within prevention and control programs. (WHO) estimates from the late 1990s indicated approximately 4 to 6 million annual cases worldwide, though current figures are likely lower due to these interventions. Periodic outbreaks persist in port cities and high-mobility urban centers, underscoring ongoing transmission risks in resource-limited settings. Underreporting substantially inflates the perceived low burden, especially in low-resource areas where syndromic treatment—treating symptoms without confirmation—is standard practice, leading to missed diagnoses and unrecorded cases. Diagnostic challenges, including the limited availability and sensitivity of tests like (less than 80% sensitive), further obscure the true global prevalence. As a result, the actual incidence in endemic regions is believed to exceed reported figures, particularly where access to specialized care is restricted. Chancroid primarily affects individuals engaging in high-risk sexual behaviors, with unprotected workers representing a key population due to frequent exposure to multiple partners in endemic regions. Men who have with men also face elevated , particularly in settings with limited access to preventive measures. Low further exacerbates vulnerability by limiting healthcare access and increasing reliance on . Behavioral factors significantly contribute to chancroid transmission, including having multiple sexual partners, inconsistent use, and travel to areas where the disease remains prevalent. These activities facilitate the spread of , the causative bacterium, through direct contact with s. Co-infection with substantially heightens the risk of acquiring chancroid, as impairs mucosal defenses and promotes bacterial persistence; studies indicate that HIV-positive individuals are more susceptible to genital ulcer diseases like chancroid. Uncircumcised males exhibit higher susceptibility compared to circumcised men, likely due to the foreskin's moist environment favoring bacterial colonization. Epidemiological trends show a substantial global decline in chancroid incidence since the , attributed to the widespread adoption of syndromic management protocols and effective single-dose antibiotics such as , which have improved adherence and reduced . In the United States, reported cases dropped from nearly 5,000 in 1987 to just a few annually by the early 2020s. However, the disease persists in resource-limited settings, with occasional outbreaks. A notable gender disparity exists in chancroid , with cases predominantly reported in males—often at ratios exceeding 10:1—owing to the visibility of penile lesions, whereas female infections frequently present with less apparent internal or remain .

History

Discovery and Early Research

Chancroid, also known as soft , was first described in 1889 by Italian dermatologist Augusto Ducrey, who identified its causative agent as a short, Gram-negative through direct microscopic examination of ulcer exudate from infected individuals. This discovery distinguished chancroid from , whose primary lesion is a firm "hard ," based on the softer, more ragged edges of chancroid and the absence of systemic progression seen in syphilitic infections. Ducrey's work laid the foundation for recognizing chancroid as a distinct sexually transmitted disease, though initial transmission experiments involved inoculating material from affected patients onto scarified skin, confirming its infectious nature without yet achieving reliable cultivation. In the 1920s, significant advances occurred in isolating and classifying the pathogen. The bacterium, initially termed Bacillus ducreyi, was successfully cultured on artificial media using techniques like blood clot , with notable contributions from researchers such as Brams in 1924, who subcultured isolates onto plates for identification. It was formally named in 1921 by Neveu-Lemaire and included in Bergey's manual in 1923, honoring Ducrey while classifying it within the Haemophilus genus due to its growth requirements for and NAD. Early during this period highlighted chancroid's prevalence in colonial and , where it was frequently linked to and migrant labor, contributing to outbreaks among urban populations and military personnel in regions like and European ports. Diagnostic methods evolved in the 1930s with the correlation of Gram staining to clinical findings; smears from bases revealed characteristic "schools of fish" arrangements of Gram-negative coccobacilli, providing a presumptive despite challenges in specificity. However, pre-1950, chancroid was often misclassified as due to overlapping ulcerative features and limited microbiological tools, leading to diagnostic confusion in endemic areas. In the 1940s and 1950s, foundational animal models were established using intradermal in rabbits to replicate formation and study , while sulfonamides became the first effective systemic following successful trials in 1938 that healed lesions in over 90% of cases without recurrence.

Modern Developments

In the 1980s, amid the emerging epidemic, chancroid was recognized as a significant cofactor in HIV transmission, as the painful genital ulcers caused by disrupt mucosal barriers and provide portals of entry for the virus. This association prompted global health responses, culminating in the World Health Organization's 1991 introduction of syndromic management guidelines for genital ulcer disease, which standardized treatment protocols for chancroid and other ulcerative sexually transmitted infections in resource-limited settings without requiring laboratory confirmation. The 1990s marked advances in diagnostic capabilities, with the development of (PCR) assays enabling more sensitive and specific detection of H. ducreyi DNA from clinical specimens, surpassing the limitations of culture-based methods that often yielded low recovery rates. Concurrently, molecular studies classified H. ducreyi strains into class I (genital ulcer-associated) and class II (cutaneous ulcer-associated) biotypes, revealing genetic distinctions that informed and . During the 2000s, reports of resistance in H. ducreyi emerged, particularly to older agents like and sulfonamides, necessitating shifts toward and cephalosporins in treatment guidelines to maintain efficacy. In 2007, the trimeric autotransporter adhesin DsrA was identified as a key and promising vaccine target, given its roles in serum resistance, binding, and bacterial adherence to host cells. From the 2010s onward, chancroid incidence declined substantially in many endemic areas, supported by broader (STI) control measures, including post-exposure prophylaxis (Doxy-PEP) trials that demonstrated up to two-thirds reduction in bacterial STI acquisition, including pathogens treatable by like H. ducreyi. Animal models advanced research, with the swine model replicating human-like ulcerative lesions and enabling evaluation of immune responses, as shown in studies immunizing against DsrA to confer protection. By 2025, multiplex real-time PCR panels for genital ulcers—detecting H. ducreyi alongside and —have become routine in laboratories, improving syndromic diagnosis accuracy and enabling targeted therapy. Integrated programs, embedding chancroid surveillance and treatment within and other initiatives, have advanced eradication goals in low-prevalence regions like parts of and , where cases are now sporadic.

References

  1. [1]
    Chancroid - STI Treatment Guidelines - CDC
    Jul 22, 2021 · Successful antimicrobial treatment for chancroid cures the infection, resolves the clinical symptoms, and prevents transmission to others.
  2. [2]
    Chancroid - StatPearls - NCBI Bookshelf - NIH
    Chancroid is an exceedingly rare sexually transmitted infection, both in the United States and globally. Understanding its true prevalence is made difficult ...Continuing Education Activity · Epidemiology · Evaluation · Treatment / Management
  3. [3]
    Chancroid: Symptoms, Diagnosis, and Treatment - DermNet
    What are the clinical features of chancroid? The time from infection during sexual contact to the onset of signs and symptoms is typically 4–10 days (range 1–35 ...
  4. [4]
    Chancroid - Infectious Diseases - Merck Manual Professional Edition
    After an incubation period of 3 to 7 days, small, painful papules appear on the genital skin or mucous membranes and rapidly break down into shallow, soft, ...
  5. [5]
  6. [6]
    Chancroid: MedlinePlus Medical Encyclopedia
    Aug 26, 2023 · The most common symptoms in women are pain with urination and intercourse. The ulcer may look like the sore of primary syphilis (chancre). ...Missing: fourchette walls
  7. [7]
    Genital ulcers caused by sexually transmitted agents - PMC
    Jul 20, 2022 · In men, they are preferentially located on the coronal sulcus, balano-preputial region, anus, and perianal region. In women, it most commonly ...Missing: shaft | Show results with:shaft
  8. [8]
    Chancroid Clinical Presentation - Medscape Reference
    Oct 3, 2025 · Individual ulcers vary in size from 1-20 mm, with 1-2 cm being the ... Transient chancroid produces an ulcer that rapidly resolves in 4 ...
  9. [9]
    Chancroid - Symptoms, Causes, Images, and Treatment Options
    Extragenital lesions have been reported on the breasts, legs, mouth, and fingers; these are rare and usually result from autoinoculation. HIV infection ...
  10. [10]
    Chancroid and human immunodeficiency virus infection – a review
    Dec 17, 2007 · Extragenital lesions can occur on the breasts, fingers, thigh, and oral mucosa. Chancroid can be differentiated from other genital ulcer ...
  11. [11]
    Chancroid: Background, Etiology, Pathophysiology
    Oct 3, 2025 · It is characterized by painful necrotizing genital ulcers that may be accompanied by inguinal lymphadenopathy. It is a highly contagious but ...
  12. [12]
    Immunopathogenesis of Haemophilus ducreyi Infection (Chancroid)
    The male-to-female ratio among patients with proven chancroid ranges from 3:1 in areas where it is endemic to as high as 25:1 in outbreak situations (67).
  13. [13]
    Gonorrhoea & its co-infection with other ulcerative, non ... - NIH
    Among ulcerative STIs, presence of syphilis was highest (36.9%), followed by herpes progenitalis (15.4%). A few cases were reported to have chancroid (0.9%) ...
  14. [14]
    Haemophilus ducreyi (Chancroid) | Johns Hopkins ABX Guide
    Mar 5, 2022 · Extra-genital lesions secondary to auto-inoculation: from genital lesions to non-genital sites such as breasts, thighs, eyes and fingers, ...Missing: mouth | Show results with:mouth
  15. [15]
    Sequence typing of Haemophilus ducreyi isolated from patients in ...
    Aug 15, 2024 · There are two classes of HD, Class I and Class II, based on the genetic diversity in several pathogenicity-related genes. Both classes were ...Missing: biotypes | Show results with:biotypes
  16. [16]
    Haemophilus ducreyi - Pathogen Safety Data Sheets - Canada.ca
    SURVIVAL OUTSIDE HOST: H. ducreyi can survive 2-4 hours (no more than a day) on a cotton swab before medium inoculation. SECTION V – FIRST AID / MEDICAL.
  17. [17]
    The Haemophilus ducreyi Serum Resistance Antigen DsrA Confers ...
    Haemophilus ducreyi is the etiologic agent of the sexually transmitted genital ulcer disease chancroid. H. ducreyi serum resistance protein A (DsrA) is a ...
  18. [18]
    The cytolethal distending toxin from the chancroid bacterium ... - JCI
    In all probability, HdCDT is the most important virulence factor in ulcer formation by H. ducreyi. Moreover, HdCDT and other CDTs may become interesting new ...
  19. [19]
    Expression of Cytolethal Distending Toxin and Hemolysin Is Not ...
    These results indicate that neither the expression of CDT, nor that of hemolysin, nor both are required for pustule formation by H. ducreyi in humans.
  20. [20]
    The cytolethal distending toxin of Haemophilus ducreyi aggravates ...
    Co-administration of HdCDT resulted in significant aggravation of H. ducreyi-induced inflammatory lesions, and development of ulcers in rabbit skin. Less ...
  21. [21]
    Immunopathogenesis of Haemophilus ducreyi Infection (Chancroid)
    Apr 1, 2002 · Thus, evasion of phagocytosis and phagocytic killing appears to be a major mechanism of bacterial survival, while invasion of host cells is not ...Missing: biofilm | Show results with:biofilm
  22. [22]
    Haemophilus ducreyi Infection Causes Basal Keratinocyte ...
    We characterized the cellular interleukin-1α (IL-1α), tumor necrosis factor alpha (TNF-α), IL-6, and IL-8 responses to H. ducreyi infection and herein describe ...Missing: bubo | Show results with:bubo
  23. [23]
    Immunohistochemical Analysis of Naturally Occurring Chancroid
    The recruitment of CD4 T lymphocytes and macrophages may in part explain the facilitation of HIV transmission in patients with chancroid. Topic:Missing: enhances | Show results with:enhances
  24. [24]
    Chancroid - Symptoms, diagnosis and treatment - BMJ Best Practice
    Feb 13, 2025 · Classically, genital chancroid presents with the acute onset of a painful genital ulcer, and is often associated with inguinal lymphadenitis.<|separator|>
  25. [25]
    [PDF] 2017 European guideline for the management of chancroid | IUSTI
    The infection is characterized by one or more genital ulcers, which are soft and painful, and regional lymphadenitis, which may develop into buboes.Missing: percentage | Show results with:percentage
  26. [26]
    Guidelines for the management of symptomatic sexually transmitted ...
    Jul 15, 2021 · These guidelines are to provide updated, evidence-informed clinical and practical recommendations on the case management of people with symptoms of STIs.Missing: evaluation | Show results with:evaluation
  27. [27]
    Chancroid Workup: Approach Considerations, Laboratory Studies ...
    Oct 3, 2025 · PCR is 96%-100% sensitive and 97%-98% specific. However, PCR is not usually performed on site, thereby causing a delay in making the diagnosis.Missing: specificity | Show results with:specificity
  28. [28]
    Laboratory Diagnosis of Chancroid Using Species-Specific Primers ...
    The sensitivity of PCR as compared with culture was 89% (59 of 66), and specificity was 79% (76 of 96). However, representative samples of the 20 culture- ...Missing: hhdA | Show results with:hhdA
  29. [29]
    Molecular Detection by PCR - Guide to Services - CNPHI
    ducreyi specific qPCR assays targeting the highly conserved 16S rRNA gene and the H.ducreyi specific “hemolysin” gene (hhdA). A sample is interpreted to be ...Missing: groEL sensitivity
  30. [30]
    The laboratory diagnosis of Haemophilus ducreyi - PMC - NIH
    Chancroid is a sexually transmitted infection caused by Haemophilus ducreyi. This fastidious, Gram-negative coccobacilli dies rapidly outside the human host, ...
  31. [31]
    Development of a Serological Test for Haemophilus ducreyi for ... - NIH
    In some of these studies, cross-reacting antibodies present in serum specimens from control patients made interpretation of the results difficult (3, 28) and ...
  32. [32]
    About Syphilis - CDC
    Jan 30, 2025 · Sores are usually (but not always) firm, round, and painless. Because the sore is painless, you may not notice it. The sore usually lasts 3 to 6 ...
  33. [33]
    [PDF] Syphilis Module - CDC Stacks
    Based on Stan's history and physical exam, what are the possible etiologic agents that should be considered in the differential diagnosis? ... • Chancroid— ...<|control11|><|separator|>
  34. [34]
    CDC Laboratory Recommendations for Syphilis Testing, United ...
    Feb 8, 2024 · Primary syphilis is characterized by single or multiple ulcerative-like lesions (chancres) that often are painless and therefore might be ...Missing: chancre | Show results with:chancre
  35. [35]
    About Genital Herpes - CDC
    Feb 20, 2024 · Genital herpes is an STI caused by two types of viruses – herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2).Screening · For Everyone · Condom Use: An Overview
  36. [36]
    Herpes - STI Treatment Guidelines - CDC
    Two types of HSV can cause genital herpes: HSV-1 and HSV-2. Most cases of recurrent genital herpes are caused by HSV-2, and 11.9% of persons aged 14–49 years ...Diagnostic Considerations · Counseling · Special Considerations
  37. [37]
    Lymphogranuloma Venereum (LGV) - STI Treatment Guidelines - CDC
    Jul 22, 2021 · LGV can cause severe inflammation and invasive infection, in contrast with C. trachomatis serovars A—K that cause mild or asymptomatic infection ...Missing: chancroid | Show results with:chancroid
  38. [38]
    Granuloma Inguinale (Donovanosis) - STI Treatment Guidelines - CDC
    Jul 22, 2021 · Clinically, the disease is characterized as painless, slowly progressive ulcerative lesions on the genitals or perineum without regional ...Missing: chancroid | Show results with:chancroid
  39. [39]
    Genital Ulcers: Differential Diagnosis and Management - PubMed
    Mar 15, 2020 · It is important to consider noninfectious etiologies such as sexual trauma, psoriasis, Behçet syndrome, and fixed drug eruptions. Genital ...
  40. [40]
    Diseases Characterized by Genital, Anal, or Perianal Ulcers - CDC
    Jul 22, 2021 · Genital herpes, syphilis, chlamydia, gonorrhea, and chancroid have been associated with an increased risk for HIV acquisition and transmission.
  41. [41]
    Primary Prevention Methods - CDC
    In addition, consistent and correct use of latex condoms reduces the risk for HPV infection and HPV-associated diseases, genital herpes, syphilis, and chancroid ...
  42. [42]
    Eradicating chancroid - SciELO - Saúde Pública
    Chancroid is a common cause of genital ulcer in all 18 countries where adult HIV prevalence surpasses 8% and is rare in countries with low-level HIV epidemics.<|separator|>
  43. [43]
    [PDF] Chancroid - Washington State Department of Health
    Nov 14, 2022 · Key STD prevention strategies include: STD prevention counseling, testing, and referral services – Individuals at risk for STD should be ...
  44. [44]
    Immunization with the Haemophilus ducreyi trimeric autotransporter ...
    ... DsrA have informed us on several characteristics of this potential vaccine candidate for chancroid. First, the humoral immune response elicited to this vaccine ...
  45. [45]
    The Haemophilus ducreyi trimeric autotransporter adhesin DsrA ...
    The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid.Missing: studies mouse load reduction
  46. [46]
    Sexually Transmitted Diseases Vaccines: Progress and Challenges
    In 1974, in a controlled experiment in Northern Canada, a crude-killed whole cell vaccine was studied with no evidence of protection; hence, it was not ...
  47. [47]
    Putative vaccine candidates and drug targets identified by reverse ...
    May 23, 2018 · The control of chancroid is difficult and the only current available treatment is antibiotic therapy; however, antibiotic resistance has been ...
  48. [48]
    Interactions of the Skin Pathogen Haemophilus ducreyi ... - Frontiers
    Feb 2, 2021 · Class I strains have a sialylated nonasaccharide (95), while Class II stains have a non-sialylated pentasaccharide (96). Deletion of either the ...Missing: biotypes | Show results with:biotypes
  49. [49]
    Chancroid - PMC - NIH
    A test of cure for chancroid is not recommended. If ulceration persists after therapy for chancroid, patients should have a repeat chancroid culture performed ...
  50. [50]
    Chancroid Treatment & Management - Medscape Reference
    Oct 3, 2025 · Patients presenting with suspected or diagnosed chancroid should undergo complete evaluation for other possible concomitant STIs and receive ...
  51. [51]
    Single dose azithromycin for the treatment of chancroid - PubMed
    Results: Cure rates were 89% (73 of 82) in the azithromycin group and 91% (41 of 45) in the erythromycin group. A failure to respond to treatment was ...
  52. [52]
    GENITAL ULCER DISEASE SYNDROME - NCBI - NIH
    Jun 10, 2021 · However, chancroid ulcers often have atypical clinical appearances and may dispel suspicion of chancroid, with some small ulcers mimicking ...10genital Ulcer Disease... · 10.1. Herpes Simplex Virus · 10.2. Syphilis
  53. [53]
    Psychological health and well-being in patients with sexually ...
    Psychological distresses are commonly associated with sexually transmitted infections (STIs) and have been reported in viral STIs. Merin and Pachankis described ...<|control11|><|separator|>
  54. [54]
    Genitourinary Infections Related to Circumcision and the Potential ...
    2) Chancroid and infertility​​ To date, there is no evidence for the impact of chancroid on infertility [83].
  55. [55]
    An Examination of National Case-Based Chancroid Surveillance - NIH
    The clinical presentation of chancroid includes painful anogenital ulcers and buboes (very inflamed and swollen lymph nodes) in the groin region. Buboes can ...
  56. [56]
    Chancroid Epidemiology - News-Medical
    The estimates are that approximately seven million cases of this disease are seen worldwide; however, under-reporting and misdiagnoses hamper accurate ...Missing: distribution | Show results with:distribution
  57. [57]
    Epidemiology of Haemophilus ducreyi Infections - PMC - NIH
    Clinical diagnosis of chancroid is often based on the appearance of the ulcer, which is characteristically painful, purulent, and deep with ragged, undermined ...
  58. [58]
    Chancroid | 5-Minute Clinical Consult - Unbound Medicine
    Endemic in developing countries; annual estimated global prevalence of 4 to 6 million; actual prevalence is unknown (2). More common in. Sub-Saharan Africa ...<|separator|>
  59. [59]
    Chancroid: clinical manifestations, diagnosis, and management - PMC
    Chancroid is a sexually transmitted disease (STD) caused by the Gram negative bacterium Haemophilus ducreyi and is characterised by necrotising genital ...Missing: definition symptoms
  60. [60]
    [PDF] Chancroid Disease Plan - Utah Epidemiology
    Aug 9, 2023 · The incubation period is typically from 4–7 days. ... All contacts of cases of chancroid exposed within 10 days of symptom onset should receive.
  61. [61]
    Chancroid - ScienceDirect.com
    Oct 3, 2025 · Chancroid has been strongly associated with commercial sex, specifically female sex workers and their male partners, which may partially explain ...
  62. [62]
    Chancroid - an overview | ScienceDirect Topics
    The name 'chancroid' derives from the fact that individuals with acute infection develop lesions which resemble the chancre of primary syphilis. In fact, ...
  63. [63]
    Biology of Haemophilus ducreyi - PMC - NIH
    ... characteristics and role as the causative agent of chancroid. Because of its fastidious growth requirements, including unknown components in blood, the ...
  64. [64]
    Species: Haemophilus ducreyi - LPSN
    n. ducreyi , of Ducrey, named after Ducrey, the bacteriologist who first isolated this organism ... Haemophilus ducreyi has for long been recognized to be only ...
  65. [65]
    Cultural Diagnosis of Chancroid | JAMA Dermatology
    Culture of Haemophilus ducreyi remains the definitive way to diagnose chancroid. Since its discovery in 1889, cultural isolation of this fastidious organism has ...
  66. [66]
    Sexually transmitted infections, their treatment and urban change in ...
    Chancroid cases were less than forty per year and LGV less than twelve. Early syphilis, chancroid and LGV incidence rates declined to levels about one ...
  67. [67]
    A clinical variant of chancroid resembling granuloma inguinale
    The pathologic process, therefore, represents a variant of chancroid having the clinical features of granuloma inguinale. Without the widespread availability ...Missing: pre- 1950
  68. [68]
    Antimicrobial Therapy of Chancroid: An Evaluation of Five Treatment ...
    riched chocolate agar containing vancomycin, (3 mg/ liter) and 5% fetal calf ... Forty-one patients had a genital ulcer considered to be chancroid despite ...
  69. [69]
    Epidemiology of Haemophilus ducreyi Infections - CDC
    Dec 17, 2015 · Haemophilus ducreyi, a fastidious gram-negative bacterium, is the causative agent of chancroid, a genital ulcer disease (GUD).
  70. [70]
    Development of a polymerase chain reaction assay for the detection ...
    Study design: A polymerase chain reaction (PCR) assay was developed to detect the presence of Haemophilus ducreyi. A pair of primers was selected from ...
  71. [71]
    Haemophilus ducreyi Cutaneous Ulcer Strains Are Nearly Identical ...
    We show that CU strains obtained from Samoa and Vanuatu are genetically nearly identical to class 1 GU strains and contain no additional genetic content.
  72. [72]
    In vitro and in vivo activity of combination antimicrobial agents on ...
    Abstract. Objectives: Development of single dose antibiotic treatments for chancroid has been followed by drug-resistant Haemophilus ducreyi in endemic areas.Missing: quinolone | Show results with:quinolone
  73. [73]
  74. [74]
    Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted ...
    Apr 5, 2023 · The combined incidence of gonorrhea, chlamydia, and syphilis was lower by two thirds with doxycycline postexposure prophylaxis than with standard care.Missing: decline | Show results with:decline
  75. [75]
    The Haemophilus ducreyi trimeric autotransporter adhesin DsrA ...
    Since DsrA has many attributes of a successful vaccine candidate, including surface expression, involvement in pathogenesis [8], [9], immunogenicity [15] ...
  76. [76]
    Evaluation of a laboratory-developed multiplex real-time PCR assay ...
    Conclusions: The GUD M-PCR assay performed well in four independent PHLs and 12 suspected syphilis cases were identified in this study. The M-PCR assay could ...
  77. [77]
    [PDF] STI National Strategic Plan 2021-2025 - HHS.gov
    Feb 18, 2020 · The STI Plan highlights opportunities to integrate STI prevention and control into HIV, viral hepatitis, substance use disorders, and other ...